Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyMasatoshi Kudo, Yasuaki Arai, Youn Jae Lee et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 200
Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)Hisashi Hidaka, Yasuaki Arai, Namiki Izumi et al.|Medical Oncology|2019Cited by 23
A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of HyperglycemiaNaoko Yamamoto, Tetsuo Nishikawa, Yuya Tsurutani et al.|Internal Medicine|2019Cited by 22
Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)Hiroko Minatogawa, Takako Eguchi Nakajima, Naoki Izawa et al.|British Journal of Cancer|2023Cited by 18